Chemically Induced Degradation of FAK-ALK for Application in Cancer Therapeutics.
作者信息
Kargbo Robert B
机构信息
Usona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States.
出版信息
ACS Med Chem Lett. 2020 Jun 8;11(7):1367-1368. doi: 10.1021/acsmedchemlett.0c00290. eCollection 2020 Jul 9.
Abstract
摘要
相似文献
1
Chemically Induced Degradation of FAK-ALK for Application in Cancer Therapeutics.化学诱导的FAK-ALK降解在癌症治疗中的应用
ACS Med Chem Lett. 2020 Jun 8;11(7):1367-1368. doi: 10.1021/acsmedchemlett.0c00290. eCollection 2020 Jul 9.
2
Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.在非小细胞肺癌和卵巢癌模型的临床前研究中发现一种新型的 ALK/ROS1/FAK 抑制剂 APG-2449。
BMC Cancer. 2022 Jul 11;22(1):752. doi: 10.1186/s12885-022-09799-4.
3
Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK).ALK 的化学诱导降解。
J Med Chem. 2018 May 10;61(9):4249-4255. doi: 10.1021/acs.jmedchem.7b01655. Epub 2018 Apr 24.
4
FAK signaling in human cancer as a target for therapeutics.FAK 信号在人类癌症中的作用及其作为治疗靶点的研究进展。
Pharmacol Ther. 2015 Feb;146:132-49. doi: 10.1016/j.pharmthera.2014.10.001. Epub 2014 Oct 12.
5
Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt.胰岛素样生长因子I可防止甘露醇诱导的粘着斑激酶和Akt降解。
J Biol Chem. 2002 Jul 26;277(30):27393-400. doi: 10.1074/jbc.M201963200. Epub 2002 May 14.
6
SY-707, an ALK/FAK/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells.SY-707，一种ALK/FAK/IGF1R 抑制剂，可抑制乳腺癌细胞的生长和转移。
Acta Biochim Biophys Sin (Shanghai). 2022 Feb 25;54(2):252-260. doi: 10.3724/abbs.2022008.
7
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).间变性淋巴瘤激酶（ALK）的蛋白水解靶向嵌合体（PROTACs）。
Eur J Med Chem. 2018 May 10;151:304-314. doi: 10.1016/j.ejmech.2018.03.071. Epub 2018 Mar 27.
8
Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment.FAK 抑制剂在癌症治疗中双重靶向能力的最新进展。
Biomed Pharmacother. 2022 Jul;151:113116. doi: 10.1016/j.biopha.2022.113116. Epub 2022 May 19.
9
Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics.小分子黏着斑激酶（FAK）抑制剂作为有前途的抗癌治疗药物的最新进展。
Curr Med Chem. 2021 Oct 27;28(34):6977-6989. doi: 10.2174/0929867328666210331143827.
10
hsp72 inhibits focal adhesion kinase degradation in ATP-depleted renal epithelial cells.热休克蛋白72（HSP72）抑制ATP耗竭的肾上皮细胞中粘着斑激酶的降解。
J Biol Chem. 2003 May 16;278(20):18214-20. doi: 10.1074/jbc.M300126200. Epub 2003 Feb 28.
引用本文的文献
1
Assessment of the metabolic stability of CEP-37440, a selective FAK/ALK inhibitor, in HLMs using fast UPLC-MS/MS method: metabolic lability and DEREK alerts screening.使用快速超高效液相色谱-串联质谱法评估选择性黏着斑激酶/间变性淋巴瘤激酶抑制剂CEP-37440在人肝微粒体中的代谢稳定性：代谢不稳定性及DEREK警报筛选
Front Chem. 2024 Sep 26;12:1323738. doi: 10.3389/fchem.2024.1323738. eCollection 2024.
2
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).PROTACs：学术和工业界的巨大机遇（2020 年至 2021 年更新）。
Signal Transduct Target Ther. 2022 Jun 9;7(1):181. doi: 10.1038/s41392-022-00999-9.
3
Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy.靶向黏着斑激酶（FAK）的药物研发：一种有前景的癌症治疗策略。
Molecules. 2021 Jul 13;26(14):4250. doi: 10.3390/molecules26144250.
本文引用的文献
1
Pharmacokinetic-Based Drug-Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review.基于药代动力学的间变性淋巴瘤激酶抑制剂的药物相互作用：综述。
Drug Des Devel Ther. 2020 Apr 30;14:1663-1681. doi: 10.2147/DDDT.S249098. eCollection 2020.
2
Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis.布加替尼和阿来替尼用于治疗伴有或不伴有中枢神经系统转移的ALK重排阳性晚期非小细胞肺癌：一项系统评价和网状Meta分析
Cancers (Basel). 2020 Apr 10;12(4):942. doi: 10.3390/cancers12040942.
3
Emerging Roles of ALK in Immunity and Insights for Immunotherapy.ALK在免疫中的新兴作用及免疫治疗见解
Cancers (Basel). 2020 Feb 12;12(2):426. doi: 10.3390/cancers12020426.
4
The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review.核焦点黏着激酶（FAK）在癌症中的作用：聚焦综述。
J Exp Clin Cancer Res. 2019 Jun 11;38(1):250. doi: 10.1186/s13046-019-1265-1.
5
Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors.焦点黏着激酶在卵巢癌中的作用：一种针对铂类和紫杉烷类耐药肿瘤的潜在治疗靶点。
Curr Cancer Drug Targets. 2019;19(3):179-188. doi: 10.2174/1568009618666180706165222.
Zotero 插件